Crescent Biopharma (CBIO) Revenue (2013 - 2026)

Crescent Biopharma (CBIO) posted quarterly Revenue of $1.0 million for Q1 2026, up 1285.33% quarter-over-quarter from $75000.0 in Q2 2022.

Crescent Biopharma (CBIO) Revenue (2013 - 2026) Analysis & Trends

Crescent Biopharma (CBIO) has reported Revenue for 8 consecutive years, with $1.0 million the latest figure, recorded in Q1 2026.

In Q1 2026, Revenue changed N/A year-over-year to $1.0 million; the TTM figure through Jun 2026 stood at $1.0 million (changed N/A YoY), while the FY2025 annual figure was $10.8 million, changed N/A from the prior year.
Revenue grew to $1.0 million in Q1 2026 per CBIO's latest filing, from $75000.0 in the prior quarter.
Across five years, Revenue topped out at $1.0 million in Q1 2026 and bottomed at $75000.0 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.52 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.29 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	425.49 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	674.14 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.06 Bn
10	Crescent Biopharma	1.05 Bn	875.92 Mn	-	-

Download Data